Prelude Therapeutics says FDA clears IND for PRT13722 in HR+/HER2- breast cancer
PRLD•FDA clears IND for PRT13722
- Prelude Therapeutics received FDA clearance for its IND for PRT13722, an oral KAT6A selective degrader for HR+/HER2- breast cancer.
- Phase 1 enrollment is expected to start in Q4 2026.
